Rationale, aims, and objectives: When randomized controlled trial data are limited or unavailable, or to supplement randomized controlled trial evidence, health technology assessment (HTA) agencies may rely on systematic reviews of nonrandomized studies (NRSs) for evidence of the effectiveness of health care interventions. NRS designs may introduce considerable bias into systematic reviews, and several methodologies by which to evaluate this risk of bias are available. This study aimed to identify tools commonly used to assess bias in NRS and determine those recommended by HTA bodies.
The changing paradigm for health care decision making has begun to welcome observational and real-world data in addressing evidence gaps. 1, 2 This move to observational data has been fuelled by greater availability and access to electronic health care data and long-term observational studies. Where randomized controlled trials (RCTs) are unavailable, unethical, or implausible, and to supplement RCT evidence, health technology assessment (HTA) agencies commonly rely on nonrandomized studies (NRS) to provide evidence of the effectiveness of health care interventions. 3, 4 Interventions for rare diseases are often approved with short-term trials and with rapid review to give patients access to drugs more quickly. However, in these cases, long-term observational data/ postmarketing studies are paramount to illustrating the long-term benefits or side effects of drug use and are commonly being mandated in marketing authorization.
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Whilst there is no doubt of the benefits of including NRS in systematic reviews, incorporation of this type of evidence into a systematic review or a meta-analysis requires careful consideration as, due to their design, NRS are especially susceptible to confounding and other types of bias. For example, allocation of patients to an intervention in a nonrandomized fashion can result in selection bias with a disproportionate distribution of known prognostic factors between treatment arms, 6 whereas performance bias may result in cases where study investigators are aware of treatment allocation. 7 Further bias may be introduced by misclassification of or deviation from an intervention, missing data, mismeasurement or misclassification of outcomes, or selective reporting. Whilst RCTs are also susceptible to these potential sources of bias, several tools including those from Cochrane, 7 the
Centre for Reviews and Dissemination (CRD), 8 and the Scottish Intercollegiate Guidelines Network (SIGN) 9 are commonly used to critically appraise studies included in a systematic review of RCTs. All published Cochrane reviews must perform an analysis with the Cochrane risk of bias (ROB) tool, 7 making it the most recognized of these tools. A recent evaluation found the Cochrane ROB tool has become the preferred approach to assess ROB in RCTs even in non-Cochrane reviews;
however, it is not always implemented in the recommended way.
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Although tools for the evaluation of NRS have existed for some time, to date, there is no consensus about which is the most suitable for use for a particular study design. For instance, although a prospective nonrandomized interventional study and a retrospective case series are both NRS by definition, there are substantial differences in their study designs and potential sources of bias that may be difficult to assess with a single tool, most of which assess only a limited spectrum of possible sources of bias. However, researchers would benefit from a consensus on a small suite of tools, which could be used for NRS, dependent on design of studies in the review. This would allow for better interpretation of the results of the ROB analysis and limit the variability in bias judgements, which have been identified as a problem in Cochrane reviews. 11 We undertook a review of the literature with the aims of identifying the most commonly used and accepted critical appraisal tools for NRS and of providing an overview of the most frequent characteristics of such tools.
| METHODS
We used a 2-part approach to address our research question. Firstly, we conducted a targeted search in MEDLINE, MEDLINE In-process and Other Non-Indexed Citations, and EMBASE (OVID SP) to identify systematic reviews that included NRS. Abstracts for the records retrieved using the search terms shown in Table S1 were reviewed by a single reviewer. To be eligible for inclusion in the narrative synthesis, reviews were required to be systematic reviews of medical inter- to studies of other interventions. As study design was not a search criterion, most identified reviews included both RCT and NRS evidence, both of which were frequently evaluated using the same critical appraisal tool: The Cochrane ROB tool for RCT 7 was used by 46 of the 686 studies identified by our search. Modified versions of the Cochrane tool were also used although details of these modifications were rarely reported. In addition, Cochrane has multiple published critical appraisal tools (Cochrane ROB, ACROBAT-NRSI, and
Frequency of appraisal tool use among 686 systematic reviews that included NRS ROBINS-I), and often studies did not clarify which tool was used; in these cases, we have recorded the tool as "Cochrane undefined" (49 of 686). The SIGN and CRD tools were used for NRS appraisal in 10 and 8 studies, respectively, although these were also designed for use on trials with a randomized controlled design only. 8, 12 For reviews that used an evidence grading tool, eg, GRADE, the review applied the criteria to a within-study comparison, and so they were considered relevant to this research question.
Of the 686 systematic reviews identified by our search strategy, 77 (11%) reported that no appraisal tool was used, and 59 (9%) did not report on the appraisal tool. Among the remaining studies, the most commonly used critical appraisal tool for NRS was the Newcastle-Ottawa Scale for observational studies, reported in 142 of 686 (21%) of the systematic reviews. The MINORS, bespoke tools, GRADE, ACROBAT-NRSI (which has since been developed into ROBINS-I), and JBI-MAStARI tools were also used by multiple studies: 68 (10%), 39
(6%), 24 (3%), 18 (3%), and 17 (2%), respectively. All remaining tools identified were used by less than 2% of the included studies. A full list of the studies included is given in Appendix S1.
Whilst a majority of studies gave a narrative summary of quality assessment, others adjusted for study quality in meta-analysis. Authors typically applied a cut-off in terms of score or domain to classify poorer quality studies and then conducted a sensitivity analysis excluding those studies.
| Appraisal tools recommended by HTA and professional groups
We reviewed the recommendations for the critical appraisal of NRS from major HTA bodies and institutions involved in developing systematic review methodologies, including Cochrane, 7 the CRD, 8 and the SIGN 12 (Table 1) . CADTH was the only HTA group to recommend a specific critical appraisal tool-that produced by the SIGN. 14 Other HTA groups reported less defined recommendations: NICE recommends that an appropriate and validated tool is used, 15 and PBAC requests that relevant documentation is provided to support the use of any tool used. 16 The process of validation that should be undertaken for the critical appraisal tool is not clearly defined. The remaining HTA groups (SMC, NCPE, AWMSG, IQWiG, AMCP, and HAS) did not mention the critical appraisal of NRS. Whilst there is recognition by HTA agencies that NRS can provide valuable information to supplement robust RCT evidence and NRS are increasingly being incorporated in HTA submissions, there is a lack of guidance or consensus as to how this data should be critically appraised. 13, 17 The recognized methodological groups, SIGN 9 and Critical Appraisal Skills Programme, 18 produce different critical appraisal tools for NRS ( 
| Overview of components of appraisal tools
An overview of the 5 most commonly used appraisal tools is given in Table 2 , which includes only those tools specifically designed for the critical appraisal of NRS. This summary may help review authors to select a critical appraisal tool for use in their systematic review. Two tools that were highly ranked, but not included here, were an undefined Cochrane tool (which could be either the Cochrane ROB tool for RCTs (not capitalised) or that from the NRS group) and the Cochrane ROB tool for RCTs. These are not included as tools to appraise RCTs are unlikely to be appropriate or sufficient for the appraisal of NRS. 21 Questions regarding methods of randomization are not applicable to NRS, and details regarding comparability of the study population may be insufficient.
To aid in interpretation and comparability, we divided the appraisal tool items into 12 domains according to the different questions posed that were common across all tools:
1. Appropriate study design-a clear aim that is precise and relevant in the context of the literature is stated.
2. Patient selection/ inclusion criteria-a clear inclusion criterion is stated. 12. Overall study assessment-is the overall study of adequate quality? Table 2 shows important domains of critical appraisal of NRS including assessment of patient selection, assessment of outcomes, and whether appropriate statistical analysis has been conducted.
These domains are based on descriptions of bias as given in the CRD guidance and the Cochrane Handbook. 7, 8 Identification of confounding and methods used to address it were also commonly queried.
The ROBINS-I tool is designed to evaluate the ROB in estimates of the comparative effectiveness of interventions in studies where participants were not randomly allocated. 6 It was developed as a collaboration between the Cochrane Bias Methods Group and the Cochrane NRS for Interventions Methods Group. It is composed of 7 core domains, which then have up to 8 individual points to be assessed;
there are a total of 34 questions over the tool's 22 pages. Each domain is rated as low, moderate, serious, or critical ROB with the overall study rating taking the rating of the worst performing domain. The tool is also accompanied by 53 pages of detailed guidance. The MINORS was designed to assess the quality of surgical intervention studies. The MINORS is composed of 8 methodological items applicable to all NRS and 4 additional items, which should be applied in the case of comparative studies. Each item scores 2 for reported and adequate, 1
for reported but inadequate, or 0 for not reported, giving a maximum score of 16 for noncomparative studies or 24 for comparative studies. 24 The Newcastle-Ottawa Quality Assessment Scale was developed as a collaboration between the Universities of Newcastle, Australia, and Ottawa, Canada, and includes separate instruments for case-control and cohort studies. There are 3 domains: selection (4 questions), comparability (1 question), and exposure (3 questions), giving a total of 8 questions. Studies can score up to 9 stars, with up to 2 stars being awarded for comparability. A brief coding manual accompanies each instrument.
The SIGN has a range of methodology checklists; for NRS, one addresses case-control studies, and a second covers cohort studies.
For cohort studies, there are 18 statements listed that reviewers check against the study; some statements are only applicable in certain cases, eg, in prospective studies, and these are indicated. For case-control studies, there are 15 statements. 9 Notes are provided for each checklist.
| DISCUSSION
This review of critical appraisal tools identified 48 different tools that were used in at least one published review. We have highlighted similarities and differences between the most commonly used tools designed specifically for use with NRS. The complexity and relevance of the tools were highly variable. Some appraisal tools included a simple answering mechanism: "yes" or "no," thus facilitating rapid completion (eg, GRACE, and JBI). Tools for assessing the quality of RCTs were frequently applied inappropriately to NRS. Whilst Cochrane does state that the ROB tool for RCTs may be useful to assess some aspects of bias in controlled studies and prospective cohort studies, this tool may not be appropriate to capture all important aspects of bias or for other NRS designs. 7 The publication of the ROBINS-I tool, and its use in Cochrane systematic reviews, may change the future landscape of commonly used NRS critical appraisal tools and is likely to be favoured in a forthcoming edition of the handbook since the current guidance is based on review from 2003. 25 As a new tool, there is a lack of published critique on its usage. However, whilst anecdotal evidence from colleagues at the Universities of Leicester and Southampton acknowledged that although a popular tool it was onerous, others found the ROBINS-I tool suitable for the inexperienced reviewer through well-defined domains and thorough guidance. 26 It also offered the ability to differentiate between poor quality studies in Gardener's analysis, 26 another frequent criticism of some of the shorter tools.
Whilst being acknowledged for its ease of use and a convenient scoring system, 25,27 the more established NOS has been criticized on concerns of lacking guidance, 28 inter-rater reliability, 29 and in terms of the validity of being a scoring system, which in this case rates each awarded "star" equally. 30 In fact, several of the tools considered here have scoring systems (eg, NOS). Scoring systems are by their nature attractive for conducting subgroup analysis or meta-regression. However, Cochrane recommends against the use of scales that provide scores, as these give equal weight to each criterion being assessed without regard to their relative importance, 7 a common criticism of the Jadad score in RCTs. Berger 31 also highlights the limitations of additive scoring systems, whereby one unacceptable domain score does not relegate a study to being poor quality. This is in contrast to the ROBINS-I tool that adopts more of a multiplicative approach; a study is rated at an overall ROB equal to its worst domain. Hence, a study is rated at serious ROB if at least one of its domains is rated as serious. The onus falls on HTA bodies to provide a clearer indication of how they wish critical appraisals to be conducted.
There is little consensus regarding which is the most appropriate critical appraisal tool to use for NRS. The different methodological quality and variability in reporting of NRS make consistent assessment of ROB difficult. 32 Whilst HTA bodies do recommend the use of a validated critical appraisal tool, this process is undefined, and we noted considerable variability in the domains assessed in each appraisal tool. Previous research has indicated that the tools are often based on the developer's concept of research quality and that more stringent validation techniques are needed. 33 We recommend that, to obtain the most meaningful indication of bias, reviewers should select the most appropriate NRS-specific appraisal tool for the studies identified by their systematic reviews.
To comment on the appropriateness of any one NRS tool is beyond the scope of this review; however, several research groups have investigated this question. For example, the Agency for Healthcare
Research and Quality recommends that the critical appraisal instrument chosen should have proven validity and transparency in how the assessments are made, be specific to the study design, and should not implement an overall composite score. 3 The use of tools designed to assess bias in RCTs should be avoided as the biases specific to NRS will not be adequately assessed by such tools. As shown by our study, appraisal tools may be specific to a particular NRS design, and some may be applicable only to prospective designs (eg, ISPOR) or to comparative studies (eg, ROBINS-I). Indeed, because of significant differences in study design, more than one tool may be necessary for any given systematic review. The interpretation and ease of use of the tool will also come into consideration: some of the tools described require considerable knowledge of study design (JBI MAStARI), whilst others have extensive domain descriptions that may take a considerable amount of time to work through (eg, ISPOR and ROBINS-I). The
Cochrane ROB tool for RCTs has a simple "traffic light" system to display an overall summary of the ROB in included studies; unfortunately, none of the tools identified for NRS offer such a straightforward but effective output. Appraisal tools that exceed the 7-item length in the Cochrane ROB tool for RCTs may be more difficult to interpret, time consuming to complete, and may be more prone to error to be used in meaningful discussions around study quality. Assessment of the quality of NRS is becoming more and more important as such evidence, together with real-world data, plays an increasingly important role in health care decision making.
| CONCLUSION
There is little consensus around the most appropriate critical appraisal tool to use for NRS. The authors believe that whilst no single tool exists that can be used to assess ROB across all study designs, a consensus on a small suite of tools that could be used for NRS, dependent on design of studies in the review, would be preferable to no guidance.
Researchers should select the most appropriate appraisal tool for the review based upon study design, focusing on those tools specific to NRS, and practical considerations such as the size of their review to provide the most meaningful indication of bias associated with included studies, whilst keeping abreast of ongoing research in this area.
